 In Part A of the study, olaparib will be administered continuously with intermittent AZD5363 in 21-day cycles. Intrapatient dose escalation of AZD5363 will be utilised to evaluate different dose levels. The optimal dose schedule selected based on toxicity, PK-PD andor efficacy data will be taken forward into two expansion cohorts in Part B of the study. Cohort 1 will comprise patients with germline BRCA12 mutated tumours, while Cohort 2 will comprise advanced sporadic cancers that may harbour HR defects e.g. TNBC, CRPC and HGSOC or those with somatic mutations or other aberrations known to result in a hyperactivated phosphatidylinositol-3-kinase PI3K-AKT pathway. 